Each year, Cure Parkinson’s produces a report to highlight the impact of our research funding in the wider Parkinson’s field and community. This analysis encompasses the previous financial year as well as the charity’s impact since its beginning in 2005.
As of March 2025, we had 33 active research projects investigating 36 individual therapeutics with a combined funding commitment of £18.7 million. Between April 2024 and March 2025, we funded 9 new research projects, totalling £8.4 million. This includes the Edmund J. Safra Accelerating Clinical Trials for Parkinson’s Disease (EJS ACT-PD) platform – the world’s largest clinical trial for Parkinson’s. In the first instance, EJS ACT-PD will recruit 1600 people with Parkinson’s across the UK, with sites opening over the next few months in England, Wales, Scotland, and Northern Ireland.
These new projects also include 2 additions to our iLCT Pipeline Research Acceleration programme. The International Linked Clinical Trials (iLCT) programme, run in partnership with Van Andel Institute, involves a committee that meets annually to review and prioritise promising treatments for clinical trials. In September 2024, the committee gathered at Van Andel Institute in Grand Rapids, Michigan to evaluate 17 drugs, with 5 being prioritised for further testing. Drugs that are promising but are missing key information to progress them further are fed into our Pipeline programme. As a result of our 2024 grant call, we funded 2 studies – one in India and one in Germany – testing a total of three potential therapies.
Since its inception, Cure Parkinson’s has awarded research funding to 41 institutions across 12 countries, with three new institutions added to the list this year. Through our grant funding programmes and other initiatives, we hope to continue to grow our international reach.
This year also marked an important one for collaboration, with two new partnerships created. The first, with France Parkinson, was to develop a MAMS consortium – a group of international stakeholders involved in the development of multi-arm, multi-stage platform trials. Secondly, alongside Alzheimer’s Research UK, we aimed to explore and identify drugs of potential benefit for both Parkinson’s and Alzheimer’s and related dementias.
All this work is only possible because of our wonderful researchers and supporters, and we thank you for all your hard work and dedication. If you are interested in reading more about our impact, the full report can be downloaded below.
Cure Parkinson’s 2025 Impact Report
In this report we evaluate the impact of our research activity, outlining the progress we have made as a charity up to March 2025. The impact of our research activity encompasses our grant funding, our International Linked Clinical Trials (iLCT) programme, our international convening of researchers and collaborators, our involvement of people with Parkinson’s in research, and our outreach about the work we do. Our updated Research Strategy, published in November 2025, provides the focus for our work going forward and we look forward to reporting on the impact arising from that in 2026.
Dr Simon Stott, Director of Research, Cure Parkinson’s
This year Cure Parkinson’s has awarded research funding to 41 institutions across 12 countries, supporting 59 individual principal investigators leading research projects aimed at slowing, stopping, or reversing Parkinson’s. I am also very proud that involving people with Parkinson’s in research is fundamental to everything we do I would like to thank our researchers and generous supporters for making our important work possible.
Helen Matthews, CEO, Cure Parkinson’s
